ライフサイエンスコーパス: beta-adrenergic agonist

1 her increase by a standard inhaled dose of a beta-adrenergic agonist.

2 ate vectorial fluid transport in response to beta-adrenergic agonists.

3 in regulating portal vein responsiveness to beta-adrenergic agonists.

4 hase of LTP also is modulated importantly by beta-adrenergic agonists.

5 iates abbreviation of systole in response to beta-adrenergic agonists.

6 drenergic agonists and dilate in response to beta-adrenergic agonists.

7 notype in white adipose tissue stimulated by beta-adrenergic agonists.

8 and its inhibitory effect can be reversed by beta-adrenergic agonists.

9 ionships, calcium handling, and responses to beta-adrenergic agonists.

10 ble for the increase in heart rate caused by beta-adrenergic agonists.

11 hich responds to low doses of cholinergic or beta-adrenergic agonists.

12 anaphylaxis, while an HR1 antagonist plus a beta-adrenergic agonist +/- a BTK antagonist is optimal

13 beta-Adrenergic agonists accelerate the clearance of alv

14 4, Y364), although both growth factors block beta-adrenergic agonist action.

15 Bucindolol exhibits approximately 60% of the beta-adrenergic agonist activity of xamoterol in normal

16 abain, high Ca(2+), lysophosphatidylcholine, beta-adrenergic agonist, acylcarnitine, and the Ca(2+) i

17 We have previously shown that beta-adrenergic agonists affect Na+-K+ pump current (Ip)

18 r isoproterenol, a rapidly acting peripheral beta-adrenergic agonist akin to adrenaline, or saline.

19 We hypothesized that the inhaled beta-adrenergic agonist albuterol would improve pulmonar

20 Isoproterenol, the beta-adrenergic agonist, also elicited protein secretion

21 to generate docked complexes for a series of beta adrenergic agonists and antagonists with a three-di

22 We examined the effect of beta-adrenergic agonists and antagonists on action poten

23 otein, termed betaARB protein, is induced by beta-adrenergic agonists and binds to beta2-receptor mRN

24 RNA binding protein (beta ARB) is induced by beta-adrenergic agonists and binds to G-protein-linked r

25 ial dysfunction, which can be prevented with beta-adrenergic agonists and cAMP.

26 -deficient mice, the contractile response to beta-adrenergic agonists and extracellular calcium is re

27 Both beta-adrenergic agonists and insulin provoke sequestrati

28 uscle and regulate other cellular functions, beta-adrenergic agonists and nitric oxide-containing com

29 those with IR had lower FEV(1) responses to beta-adrenergic agonists and systemic corticosteroids.

30 Combinations of an HR1 antagonist, a beta-adrenergic agonist, and a Syk or a BTK inhibitor pr

31 in mouse hearts exposed to isoproterenol, a beta-adrenergic agonist, and isoproterenol-induced incre

32 Histamine receptor 1 (HR1) antagonists, beta-adrenergic agonists, and a spleen tyrosine kinase (

33 ion inhaled corticosteroids with long-acting beta-adrenergic agonists, and anti-IgE.

34 , in the rodent, by factors such as insulin, beta-adrenergic agonists, and glucocorticoids (GCs).

35 n response to adenosine, prostaglandin E(2), beta-adrenergic agonists, and other mediators, is a mean

36 Inhaled beta-adrenergic agonists are the most commonly used medi

37 Caffeine and beta-adrenergic agonists are well-recognised drugs that

38 ervous system (SNS) and can be stimulated by beta-adrenergic agonists, at least in animals.

39 rge-White)) were administered Ractopamine (a beta-adrenergic agonist; BA; 20 ppm in feed) or Reporcin

40 Administration of beta-adrenergic agonist bronchodilators to patients with

41 able therapies including corticosteroids and beta-adrenergic agonist bronchodilators.

42 ngineered a Frizzled-2 chimera responsive to beta-adrenergic agonist by using the ligand-binding doma

43 We computed bias factors for a number of beta-adrenergic agonists by comparing BRET assays of rec

44 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylati

45 including leukotriene modifiers, long-acting beta-adrenergic agonists, combination inhaled corticoste

46 We studied whether beta-adrenergic agonists could restore lung edema cleara

47 eoblasts regulate their proliferation, and a beta-adrenergic agonist decreases bone mass in leptin-de

48 The beta-adrenergic agonist dobutamine was infused via a per

49 ip, and blunted contractile responses to the beta-adrenergic agonist dobutamine.

50 hearts but was normalized with supply of the beta-adrenergic agonist dobutamine.

51 Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and

52 In-vitro, beta-adrenergic agonists (epinephrine or metaproterenol)

53 The beta-adrenergic agonist failed to elicit a significant n

54 Isoproterenol (beta-adrenergic agonist) failed to alter plasma leptin b

55 beta-Adrenergic agonists have been selected as model com

56 le treatments of inhaled corticosteroids and beta-adrenergic agonists; however, 5-10% have severe dis

57 The modulation of the exchanger by a beta-adrenergic agonist in whole-cell clamped ventricula

58 ow responses to brachial artery infusions of beta-adrenergic agonists in healthy men.

59 ity of peripheral blood mononuclear cells to beta-adrenergic agonists in patients with heart failure

60 3K inhibition could potentiate the effect of beta-adrenergic agonists in the treatment of obesity and

61 beta-adrenergic agonists increase active Na(+) transport

62 Beta-adrenergic agonists increase ATPase activity throug

63 beta-adrenergic antagonists, indicating that beta-adrenergic agonists increase the metabolism of BAT.

64 Both alpha1- and beta-adrenergic agonists increase the severity of global

65 The data suggest that beta-adrenergic agonists increased alveolar fluid reabso

66 Beta-adrenergic agonists induce protein kinase A (PKA) p

67 oponin I (cTnI) contributes significantly to beta-adrenergic agonist-induced acceleration of myocardi

68 beta-Adrenergic agonist-induced desensitization was sign

69 s blocks L-LTP; conversely, application of a beta-adrenergic agonist induces the L-LTP.

70 aseline temperature was seen before or after beta-adrenergic agonist injection.

71 In combination with beta-adrenergic agonists, insulin stimulates internaliza

72 er small infusions of isoproterenol (ISO), a beta-adrenergic agonist, into MS alter behavioral, EEG,

73 of amylase secretion from parotid glands by beta-adrenergic agonists is mediated by the activation o

74 Additional administration of the beta-adrenergic agonist isoprenaline (1 microM) or the m

75 The beta-adrenergic agonist isoprenaline (10 microM) also ac

76 gic responses, the sensitivity of ICa to the beta-adrenergic agonist isoprenaline (Iso) was studied i

77 hibited the Ca(2+) current stimulated by the beta-adrenergic agonist isoprenaline (Iso), and washout

78 current (ICa,L) previously stimulated by the beta-adrenergic agonist isoprenaline (Iso).

79 d vessels were treated with the nonselective beta-adrenergic agonist isoproterenol (10(-5) M), both a

80 50 muM), sodium nitroprusside (200 muM), and beta-adrenergic agonist isoproterenol (100 nmol/L).

81 Cardiac responses to beta-adrenergic agonist isoproterenol (2 mg/kg) plus caf

82 hythmogenic index, 4.10; n = 8 cells) or the beta-adrenergic agonist isoproterenol (arrhythmogenic in

83 eased lipolysis in response to 10 muM of the beta-adrenergic agonist isoproterenol (by 42%), 10 muM o

84 subthreshold concentration (1 nmol/L) of the beta-adrenergic agonist isoproterenol (Iso), genistein c

85 sitivity of the Cl- current to the selective beta-adrenergic agonist isoproterenol (Iso), which indic

86 m nitroprusside (0.1 mmol/L), suppressed the beta-adrenergic agonist isoproterenol (ISO, 1 mumol/L)-s

87 The beta-adrenergic agonist isoproterenol (ISO; 1 muM) incre

88 MP) in the pipette or in the presence of the beta-adrenergic agonist isoproterenol (isoprenaline; ISO

89 been treated in vivo with milrinone, to the beta-adrenergic agonist isoproterenol and the muscarinic

90 Using the beta-adrenergic agonist isoproterenol as a specific path

91 e integrated syncytium was responsive to the beta-adrenergic agonist isoproterenol as well as to othe

92 For comparison, the beta-adrenergic agonist isoproterenol caused a 38 % incr

93 m the membrane induced by cholera toxin, the beta-adrenergic agonist isoproterenol caused a rapid par

94 ication of noradrenaline or of the selective beta-adrenergic agonist isoproterenol decreased gap junc

95 Challenge of Zmpste24(-/-) mice with the beta-adrenergic agonist isoproterenol did not trigger ve

96 The beta-adrenergic agonist isoproterenol failed to increase

97 The beta-adrenergic agonist isoproterenol increased lung liq

98 Here, we found that the beta-adrenergic agonist isoproterenol induced mature bet

99 t induce LTP, but the addition of either the beta-adrenergic agonist isoproterenol or the cAMP analog

100 In both rat and human strips, the full beta-adrenergic agonist isoproterenol raised cAMP levels

101 Stimulation of LQT2 cells with beta-adrenergic agonist isoproterenol resulted in prolon

102 amp experiments in isolated VMs treated with beta-adrenergic agonist isoproterenol showed a reduction

103 Membrane-permeable 8-bromo-cAMP and the beta-adrenergic agonist isoproterenol significantly reve

104 pressing the chimera (beta2AR-Rfz1) with the beta-adrenergic agonist isoproterenol stimulated stabili

105 ino]-5'-N-ethylcarboxamidoadenos ine and the beta-adrenergic agonist isoproterenol were additive, ind

106 P levels (including PGE2, forskolin, and the beta-adrenergic agonist isoproterenol) can inhibit P2Y r

107 synaptic stimulation in the presence of the beta-adrenergic agonist isoproterenol, a combination tha

108 ttenuates the vasorelaxation response to the beta-adrenergic agonist isoproterenol, without affecting

109 revented the Mg(2+) extrusion induced by the beta-adrenergic agonist isoproterenol.

110 cAMP levels that were pre-elevated with the beta-adrenergic agonist isoproterenol.

111 e beta-adrenergic blocker metoprolol and the beta-adrenergic agonist isoproterenol.

112 d a dose-dependent inotropic response to the beta-adrenergic agonist isoproterenol.

113 nsients caused by high concentrations of the beta-adrenergic agonist isoproterenol.

114 by treatment with a single high dose of the beta-adrenergic agonist isoproterenol.

115 and it was blocked in cells pretreated with beta-adrenergic agonist isoproterenol.

116 ardiomyocytes following stimulation with the beta-adrenergic agonist isoproterenol.

117 xtended to describe myocyte responses to the beta-adrenergic agonist isoproterenol.

118 Intraperitoneal injection of a beta-adrenergic agonist (isoproterenol) enhances SIRT2 e

119 KA) in VSMC as profoundly as the G(s)-linked beta-adrenergic agonist, isoproterenol (ISO), but in a t

120 gonist, clonidine (CLON; 0.6 mg/kg BW), or a beta-adrenergic agonist, isoproterenol (ISO; 0.2 mg/kg B

121 hibits PKA activities at the SR induced by a beta-adrenergic agonist, isoproterenol, and subsequently

122 A single injection of the beta-adrenergic agonist, isoproterenol, induced a dramat

123 Pretreatment with a beta-adrenergic agonist, isoproterenol, or a cAMP analog

124 enylyl cyclase activator, forskolin, and the beta-adrenergic agonist, isoproterenol, to lamina A1 of

125 and attenuated contractile responses to the beta-adrenergic agonist, isoproterenol.

126 eased amount of high affinity binding of the beta-adrenergic agonist, isoproterenol.

127 ling activated by parathyroid hormone or the beta-adrenergic agonist, isoproterenol.

128 These findings suggest that beta-adrenergic agonists lead to functional benefit in t

129 protein, vasoactive intestinal peptide, and beta-adrenergic agonists, like isoproterenol.

130 elines for COPD and asthma recommend inhaled beta-adrenergic agonists, muscarinic antagonists, and, f

131 The combined alpha- and beta-adrenergic agonist norepinephrine (NE) activated th

132 re, prolonged fasting, and administration of beta-adrenergic agonists (norepinephrine and CL-316243).

133 This study evaluated the effect of various beta-adrenergic agonists on (18)F-FDG uptake in brown ad

134 ies to investigate the actions of alpha- and beta-adrenergic agonists on Na+-K+ pump current.

135 l to the inotropic and lusitropic effects of beta-adrenergic agonists on the heart.

136 effects of ephedrine sulfate, an alpha- and beta-adrenergic agonist, on subjective and physiological

137 t E1 state was observed after treatment with beta-adrenergic agonist or with coexpression of phosphom

138 ts that increase intracellular cAMP, such as beta-adrenergic agonists or Bt2cAMP itself, decreased ob

139 angiocyte secretion in response to secretin, beta-adrenergic agonists, or changes in [HCO(3)(-)](i),

140 ted inhibition of Ca(2+) channel activity by beta-adrenergic agonists/PKA also requires this rigid li

141 rdiomyocytes from GRK5-knockout (KO) mice to beta-adrenergic agonists, pretreatment of GRK5-KO cardio

142 These studies indicate that cAMP and beta-adrenergic agonists produce distinct short and long

143 Moreover, stimulation of NRCs with beta-adrenergic agonists reduces FRET between NcMyBP-C a

144 dings suggest that the suppressive effect of beta-adrenergic agonists requires the presence of the P-

145 Administration of beta-adrenergic agonist restored the expression of presy

146 Beta-adrenergic agonists restored AFR in rats exposed to

147 ce were small and insensitive to insulin and beta-adrenergic agonists resulting in reduced adipocyte

148 cits because intra-hippocampal injections of beta-adrenergic agonists reversed cell death.

149 The beta-adrenergic agonists salbutamol and ephedrine have p

150 d isoproterenol, a rapidly acting peripheral beta-adrenergic agonist similar to adrenaline, to induce

151 to intravenous infusions of isoproterenol, a beta-adrenergic agonist similar to adrenaline.

152 Beta-adrenergic agonists stimulate cardiac contractility

153 Here we identify the mechanism by which beta-adrenergic agonists stimulate voltage-gated calcium

154 a novel role for TGF-beta1 in impairing the beta- adrenergic agonist-stimulated alveolar fluid clear

155 regulates both peripheral vascular tone and beta-adrenergic agonist-stimulated cardiac contractility

156 Although it is well known that beta-adrenergic agonist stimulation increases alveolar e

157 V)beta to alpha(1C) I-II loop and eliminated beta-adrenergic agonist stimulation of Ca(V)1.2 current.

158 levated basal lipolysis that is resistant to beta-adrenergic agonist stimulation, and are cold-sensit

159 The beta-adrenergic agonist terbutaline produced changes in

160 ithelial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 res

161 idney cell stimulation with isoproterenol, a beta-adrenergic agonist that activates adenylyl cyclase,

162 Bath application of isoproterenol (1 muM), a beta-adrenergic agonist that activates PKA, significantl

163 HR) after administration of isoproterenol, a beta-adrenergic agonist that increases circulating level

164 portantly, 3OST2 transcription is blocked by beta-adrenergic agonists that activate the pineal melato

165 Pharmacological treatment with a beta-adrenergic agonist to stimulate lipolysis evoked a

166 cyclase pathway, attenuating the ability of beta-adrenergic agonists to act following stimulation of

167 ion, OXT serves to facilitate the ability of beta-adrenergic agonists to fully promote lipolysis.

168 ed exposure to cognitive novelty and/or oral beta-adrenergic agonists to lessen the effects of Abeta

169 ty of both beta(3)-selective and nonspecific beta-adrenergic agonists to stimulate lipolysis is marke

170 The stimulation of lipolysis by beta-adrenergic agonists triggers rapid phosphorylation

171 DR), and torsade de pointes (TdP) induced by beta-adrenergic agonists under conditions mimicking the

172 ered as relevant in the context of detecting beta-adrenergic agonists use in animals.

173 structural similarities of NNK with classic beta-adrenergic agonists, we tested the hypothesis that

174 ctile parameters and inotropic response to a beta-adrenergic agonist were measured in isolated trabec

175 the bilayer by isoproterenol, a nonspecific beta adrenergic agonist, were both blocked by pretreatme

176 ut did not attenuate stimulatory response to beta-adrenergic agonists when reconstituted heterologous

177 ng inotropic and lusitropic tachyphylaxis to beta-adrenergic agonist, which likely contributes to its

178 ludes extrarenal factors such as insulin and beta-adrenergic agonists, which stimulate the movement o

179 an exogenous NO donor), and isoproterenol (a beta-adrenergic agonist whose vasodilator effect stems f

180 ced by stimulation of isoproterenol (ISO), a beta-adrenergic agonist with a peak at approximately 12

181 , HCO(3)(-)/CO(2), cholinergic agonists, and beta-adrenergic agonists, with or without selected inhib

182 Mice chronically fed a beta-adrenergic agonist without EE were protected from h